Sartorius AG · XETR:SRT
Sartorius — Investor Presentation (2021)
25 slides from Sartorius's investor presentation, Sep 4, 2021
Slide 1: This is Sartorius
This is Sartorius Company Presentation | 2021
Slide 2: Partner of life science research and the biopharmaceutical industry
Partner of life science research and the biopharmaceutical industry Our mission We empower scientists and engineers to simplify and accelerate progress in life science and bioprocessing, enabling the development of new and better therapies and more affordable medicine. Our vision We are a magnet and
Slide 3: Pacesetter for more than 150 years
Pacesetter for more than 150 years 1870 Florenz Sartorius, a 24-year-old, continues to develop a weighing technology that reduces the time for Evolving from a mechanical balance beam stabilization, substantially accelerating workshop into a leading lab experiments as a result. life science group 192
Slide 4: Sartorius in brief
Sartorius in brief 60+ Locations worldwide, headquartered in Göttingen, Germany 10,600+ Employees1 ~€2.3bn Sales revenue1 29.6% EBITDA margin1,2 ~€23.6bn ~35% ~40% ~25% Sartorius AG market capitalization; Sales revenue Sales revenue Sales revenue included in relevant indices in Germany Americas EMEA
Slide 5: Strong company values are the basis of all our activities
Strong company values are the basis of all our activities Sustainability Openness Enjoyment Growing profitably and acting Driving change and progress Working in an energetic and responsibly towards all stakeholders internally and externally rewarding environment 5 This is Sartorius
Slide 6: Strategic focus on the biopharma market
Strategic focus on the biopharma market Bioprocess Solutions Division Molecule Cell line and Upstream & development process development downstream production Quality | Testing | Validation Lab Products & Services Division 6 This is Sartorius
Slide 7: Attractive market environment with strong growth opportunities
Attractive market environment with strong growth opportunities Favorable ~9bn people by 2050; demographics >2bn 60 years or older Rise of ~30% CAGR for biosimilar ~10% CAGR biosimilars sales in 2020–2025 for biopharma market 2020–2025 Strong R&D pipeline; advances in gene and >40% share of biologics
Slide 8: What are biopharmaceuticals?
What are biopharmaceuticals? Active agent Manufacturing Administration Advantages Biopharmaceuticals Chemical drugs First-time or improved treatment of serious illnesses, such as cancer, multiple sclerosis, rheumatism Targets only diseased cells; fewer side effects Small molecules Chemical synth
Slide 9: Our products are widely used in the development and production of biologics against COVID-19
Our products are widely used in the development and production of biologics against COVID-19 Pandemic crisis with significantly different 200+ companies effects developing coronavirus High demand related to the development and vaccines production of vaccines and therapeutics against COVID-19; cons
Slide 10: The development and manufacture of biopharmaceuticals are complex
The development and manufacture of biopharmaceuticals are complex 10 This is Sartorius
Slide 11: Only one out of 10,000 new drug candidates reaches the market
Only one out of 10,000 new drug candidates reaches the market Drug Preclinical testing and Clinical Drug discovery further development trials approval 4-5 years 1 year 4-7 years 1-2 years >€2bn ~10% >10 years Average costs of developing Probability of clinical success From drug discovery a successfu
Slide 12: The consequence: Biotech medications are extremely expensive
The consequence: Biotech medications are extremely expensive HUMIRA® ZOLGENSMA® Annual revenue of $18 billion; is used to treat rheumatism and Currently the world‘s most expensive medical drug; other inflammatory autoimmune diseases, such as Crohn’s gene therapy used to treat spinal muscular atrophy
Slide 13: Our ambition: Reduce costly trial & error in drug discovery
Our ambition: Reduce costly trial & error in drug discovery Our laboratory tools support researchers ... ... in understanding diseases ... in conducting experiments and evaluating their data ... in identifying the right molecules and developing new medicines 13 This is Sartorius
Slide 14: Our solution: Technologies to accelerate drug discovery and development
Our solution: Technologies to accelerate drug discovery and development Molecule development Cell line development Identification / Library Lead Candidate Gene Cell line Cell line Cell validation screening optimization characterization cloning selection characterization banking products Key Sartocle
Slide 15: Our goal: Simplify manufacturing of biopharmaceuticals
Our goal: Simplify manufacturing of biopharmaceuticals Our technologies empower engineers in the biopharma industry to ... ... set up robust, flexible and safe processes for industrial production ... reduce setup costs ... enhance product yield 15 This is Sartorius
Slide 16: Our solution: Innovative technologies for all phases of drug production
Our solution: Innovative technologies for all phases of drug production Products Scalable single-use technologies for the production of biopharmaceuticals and digital tools for biopharma data analytics Application areas Filtration Cell culture technology & media Biopharmaceutical manufacturing Q
Slide 17: The widest offering of solutions in the industry
The widest offering of solutions in the industry Upstream Production of the desired drug Culture media Seed cultivation Scale-up Production Clarification & preparation centrifugation Downstream Isolation and filling of the desired drug Final Cryo- Sterile Concen- Virus Polishing Chromato- Viral fill
Slide 18: Flexible production systems are becoming more and more prevalent
Flexible production systems are becoming more and more prevalent Classic stainless steel plants Flexible systems with sterile bags High initial investment outlay Faster setup and lower investment High cleaning effort and expense throughout the entire life cycle Risk of contamination Lower consumptio
Slide 19: Data analytics has huge potential for the biopharmaceutical industry
Data analytics has huge potential for the biopharmaceutical industry Sartorius supports its customers in the digitalization and automation of their processes with its leading software for Data aggregation analysis of bioprocess data. Enhanced process control and robustness Improved product quality P
Slide 20: Leading market positions worldwide in both segments
Leading market positions worldwide in both segments Fluid Lab Microbiological Lab Fermentation Filtration Purification Pipettes management balances analysis filtration #1 #1 #3 #3 #2 #2 #3 #4 20 This is Sartorius
Slide 21: Acquisitions strengthen and differentiate the Sartorius portfolio
Acquisitions strengthen and differentiate the Sartorius portfolio Essen Life science assets from Intellicyt ViroCyt BioScience Danaher 2015 2016 2017 2018 2019 2020 2021 Bio Cellca kSep Umetrics Biological BIA WaterSep Outsource Industries Separations Acquired technologies include Automated multi-
Slide 22: Sales revenue has doubled over the last five years
Sales revenue has doubled over the last five years +30.2% Sales CAGR. 2400 ~15% ~€2.34bn 39 +14.8% EBITDA margin1 +9.9pp 2200 37 2000 +13.2% 35 1800 +9.3% 33 +18.2% 1600 +16.0% 31 1400 +12.6% 29 +8.8% ~€1.12bn 29.6 +13.6% 1200 27 1000 27.1 25 25.1 25.9 800 ~€650m 25.0 23 600 23.6 21 20.5 21.0 19.7 2
Slide 23: Sartorius 2025 ambition and initiatives
Sartorius 2025 ambition and initiatives Strategic initiatives 2025 targets Regional Participate in strong Chinese market growth Continue to outperform the important U.S. market ~ €5bn Sales revenue Portfolio Add high-impact innovations, e.g., digital tools Enhance process development capabil
Slide 24: Expansion of production capacities will be significantly accelerated and extended
Expansion of production capacities will be significantly accelerated and extended Guxhagen, Germany Göttingen, Germany Capacity expansion for bioreactors New facility for membrane production; and other equipment for the production 12,000 m² extension for existing R&D capacities of biopharmaceuticals
Slide 25: Thank you.
Thank you.